Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
C Horbinski, T Berger, RJ Packer, PY Wen - Nature Reviews Neurology, 2022 - nature.com
A new edition of the WHO classification of tumours of the CNS was published in 2021.
Although the previous edition of this classification was published just 5 years earlier, in …
Although the previous edition of this classification was published just 5 years earlier, in …
Diffuse glioma heterogeneity and its therapeutic implications
JG Nicholson, HA Fine - Cancer discovery, 2021 - AACR
Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …
characterized by minimally effective genotype-targeted therapies. Recent advances have …
Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology
D Sturm, D Capper, F Andreiuolo, M Gessi… - Nature medicine, 2023 - nature.com
The large diversity of central nervous system (CNS) tumor types in children and adolescents
results in disparate patient outcomes and renders accurate diagnosis challenging. In this …
results in disparate patient outcomes and renders accurate diagnosis challenging. In this …
A summary of the inaugural WHO classification of pediatric tumors: transitioning from the optical into the molecular era
SM Pfister, M Reyes-Múgica, JKC Chan, H Hasle… - Cancer discovery, 2022 - AACR
Pediatric tumors are uncommon, yet are the leading cause of cancer-related death in
childhood. Tumor types, molecular characteristics, and pathogenesis are unique, often …
childhood. Tumor types, molecular characteristics, and pathogenesis are unique, often …
The 2021 WHO classification of tumors of the central nervous system: a summary
The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS),
published in 2021, is the sixth version of the international standard for the classification of …
published in 2021, is the sixth version of the international standard for the classification of …
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
AV Desai, GW Robinson, K Gauvain, EM Basu… - Neuro …, 2022 - academic.oup.com
Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the
treatment of adults and children aged≥ 12 years with NTRK fusion-positive solid tumors and …
treatment of adults and children aged≥ 12 years with NTRK fusion-positive solid tumors and …
2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist
The fifth edition of the World Health Organization Classification of Tumours of the Central
Nervous System (WHO CNS5) published in 2021 builds on the 2016 edition and …
Nervous System (WHO CNS5) published in 2021 builds on the 2016 edition and …
Molecular biomarker testing for the diagnosis of diffuse gliomas: guideline from the College of American Pathologists in collaboration with the American Association of …
Context.—The diagnosis and clinical management of patients with diffuse gliomas (DGs)
have evolved rapidly over the past decade with the emergence of molecular biomarkers that …
have evolved rapidly over the past decade with the emergence of molecular biomarkers that …
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
F Doz, CM Van Tilburg, B Geoerger… - Neuro …, 2022 - academic.oup.com
Background Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase
(TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive …
(TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive …
[HTML][HTML] Major features of the 2021 WHO classification of CNS tumors
HL Smith, N Wadhwani, C Horbinski - Neurotherapeutics, 2022 - Elsevier
Advances in the understanding of the molecular biology of central nervous system (CNS)
tumors prompted a new World Health Organization (WHO) classification scheme in 2021 …
tumors prompted a new World Health Organization (WHO) classification scheme in 2021 …